share_log

6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

6-K:Sarclisa誘導治療顯著改善符合移植條件的新診斷多發性骨髓瘤患者的無進展生存期
美股SEC公告 ·  2024/08/13 05:10
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息